AxoGen, Inc. (NASDAQ:AXGN) had its price target increased by Lake Street Capital from $22.00 to $26.00 in a research note published on Tuesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

AXGN has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed a buy rating and issued a $18.00 price objective on shares of AxoGen in a research note on Monday, August 21st. Leerink Swann upped their price objective on shares of AxoGen from $23.00 to $26.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. Roth Capital reaffirmed a buy rating and issued a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. BidaskClub cut shares of AxoGen from a strong-buy rating to a buy rating in a research note on Friday, July 28th. Finally, Wedbush reaffirmed a buy rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $24.40.

Shares of AxoGen (AXGN) opened at $26.05 on Tuesday. AxoGen has a 12 month low of $8.05 and a 12 month high of $26.45. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The company had revenue of $16.05 million during the quarter, compared to analysts’ expectations of $15.55 million. The business’s revenue for the quarter was up 43.2% compared to the same quarter last year. equities analysts expect that AxoGen will post -0.33 EPS for the current fiscal year.

In related news, Director Robert James Rudelius sold 16,143 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $18.00, for a total transaction of $290,574.00. Following the completion of the sale, the director now directly owns 43,273 shares in the company, valued at approximately $778,914. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Guido J. Neels sold 1,150,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $19.74, for a total transaction of $22,701,000.00. The disclosure for this sale can be found here. Corporate insiders own 9.33% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. raised its holdings in AxoGen by 575.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 5,750 shares during the last quarter. Bank of America Corp DE raised its holdings in AxoGen by 8.7% during the 1st quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 814 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in AxoGen by 0.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 93 shares during the last quarter. Neuberger Berman Group LLC bought a new stake in AxoGen during the 2nd quarter valued at $201,000. Finally, Valeo Financial Advisors LLC bought a new stake in AxoGen during the 3rd quarter valued at $244,000. Institutional investors own 67.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/axogen-inc-axgn-price-target-raised-to-26-00-at-lake-street-capital/1725472.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.